ALNYLAM PHARMACEUTICALS, INC.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $390,000.00 expenses · posted Jul 20, 2025

Lobbying activity 2

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act.

Trade (domestic/foreign)

Issues relating to supply chain tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.